AAAAAA
Results: 26-40/40
Authors:
Tugwell, P
Wells, G
Strand, V
Maetzel, A
Bombardier, C
Crawford, B
Dorrier, C
Thompson, A
Citation: P. Tugwell et al., Clinical, improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis - Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial, ARTH RHEUM, 43(3), 2000, pp. 506-514
Authors:
Strand, V
Morgan, SL
Baggott, JE
Alarcon, GS
Citation: V. Strand et al., Folic acid supplementation and methotrexate efficacy: comment on articles by Schiff, Emery et al, and others, ARTH RHEUM, 43(11), 2000, pp. 2615-2616
Authors:
Fox, RI
Herrmann, ML
Frangou, CG
Wahl, GM
Morris, RE
Strand, V
Kirschbaum, BJ
Citation: Ri. Fox et al., Mechanism of action for leflunomide in rheumatoid arthritis, CLIN IMMUNO, 93(3), 1999, pp. 198-208
Authors:
Isaacs, JD
Morgan, AW
Strand, V
Citation: Jd. Isaacs et al., Combination biologic therapy, CLIN EXP RH, 17(6), 1999, pp. S121-S124
Authors:
Strand, V
Citation: V. Strand, Steroid withdrawal favours joint erosion in rheumatoid arthritis, CLIN EXP RH, 17(5), 1999, pp. 519-520
Authors:
Molenaar, ETH
Boers, M
van der Heijde, DMFM
Alarcon, G
Bresnihan, B
Cardiel, M
Edmonds, J
Felson, D
Furst, DE
Kirwan, J
Lassere, M
Paulus, H
Rau, R
van Riel, PLCM
Scott, D
Simon, L
Strand, V
Citation: Eth. Molenaar et al., Imaging in rheumatoid arthritis: Results of group discussions, J RHEUMATOL, 26(3), 1999, pp. 749-751
Authors:
Strand, V
Gladman, D
Isenberg, D
Petri, M
Smolen, J
Tugwell, P
Citation: V. Strand et al., Outcome measures to be used in clinical trials in systemic lupus erythematosus, J RHEUMATOL, 26(2), 1999, pp. 490-497
Authors:
Smolen, JS
Strand, V
Cardiel, M
Edworthy, S
Furst, D
Gladman, D
Gordon, C
Isenberg, DA
Klippel, JH
Petri, M
Simon, L
Tugwell, P
Wolfe, F
Citation: Js. Smolen et al., Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: Consensus on a preliminary core set of outcome domains, J RHEUMATOL, 26(2), 1999, pp. 504-507
Authors:
Boers, M
Brooks, P
Strand, V
Tugwell, P
Citation: M. Boers et al., Introduction - OMERACT IV: Fourth International Consensus Conference on Outcome Measures in Rheumatology, J RHEUMATOL, 26(1), 1999, pp. 199-200
Authors:
Gazarian, M
Tugwell, P
Boers, M
Bombardier, C
Brooks, P
Day, R
Strand, V
Wells, G
Citation: M. Gazarian et al., Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT drug toxicity working party, J RHEUMATOL, 26(1), 1999, pp. 207-209
Authors:
Olsen, NJ
Strand, V
Kremer, JM
Citation: Nj. Olsen et al., Leflunomide for the treatment of rheumatoid arthritis, B RHEUM DIS, 48(8), 1999, pp. 1-4
Authors:
Strand, V
Tugwell, P
Bombardier, C
Maetzel, N
Crawford, B
Dorrier, C
Thompson, A
Wells, G
Citation: V. Strand et al., Function and health-related quality of life - Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis, ARTH RHEUM, 42(9), 1999, pp. 1870-1878
Authors:
Weinblatt, ME
Kremer, JM
Coblyn, JS
Maier, AL
Helfgott, SM
Morrell, M
Byrne, VM
Kaymakcian, MV
Strand, V
Citation: Me. Weinblatt et al., Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis, ARTH RHEUM, 42(7), 1999, pp. 1322-1328
Authors:
Strand, V
Cohen, S
Schiff, M
Weaver, A
Fleischmann, R
Cannon, G
Fox, R
Moreland, L
Olsen, N
Furst, D
Caldwell, J
Kaine, J
Sharp, J
Hurley, F
Loew-Friedrich, I
Citation: V. Strand et al., Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate, ARCH IN MED, 159(21), 1999, pp. 2542-2550
Authors:
Maetzel, A
Bombardier, C
Strand, V
Tugwell, P
Wells, G
Citation: A. Maetzel et al., How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: A survey, J RHEUMATOL, 25(12), 1998, pp. 2331-2338